How Long Does Mounjaro Stay in Your System? Half-Life and What to Expect

If you are taking Mounjaro (tirzepatide) for weight loss or type 2 diabetes, you may wonder how long the medication stays in your body after your last injection. Whether you are planning a break from treatment, preparing for surgery, or thinking about pregnancy, understanding the drug’s half-life and clearance timeline helps you plan ahead with confidence.

This guide covers what the clinical evidence tells us about tirzepatide’s duration in the body, what to expect as the drug clears, and when its effects typically wear off.

A drug’s half-life is the time it takes for half the active substance to be eliminated from your bloodstream. For any medication, it generally takes around five half-lives for the drug to be considered fully cleared from the body.

Understanding this is particularly important for injectable medications like Mounjaro, which are designed to remain active for longer periods between doses. The half-life determines how often you inject, how long side effects may last, and how quickly the drug’s effects fade once you stop.

According to the prescribing information published by Eli Lilly and the MHRA Summary of Product Characteristics, tirzepatide has a half-life of approximately five days (around 120 hours). This is why Mounjaro is administered as a once-weekly injection.

Pharmacokinetic studies confirm that steady-state concentrations are typically reached after four weeks of weekly dosing. At steady state, the drug maintains a consistent therapeutic level in your bloodstream throughout the week.

Using the five half-lives rule, tirzepatide takes approximately 25 days to be essentially eliminated from your body after your final injection.

After 5 days (one half-life), roughly 50% of the drug remains. After 10 days, about 25% remains. After 15 days, approximately 12.5% remains. After 20 days, around 6% remains. By 25 days after your last dose, the drug is considered clinically cleared, with less than 3% remaining.

Individual factors such as kidney function, body weight, and dose level may influence clearance slightly, but the 25-day window is a reliable general guide.

As tirzepatide clears from your system, its effects on appetite suppression and blood sugar regulation gradually diminish. Most patients notice a return of appetite within one to two weeks after their last injection. Blood sugar levels in people with type 2 diabetes may also begin rising during this period.

Gastrointestinal side effects such as nausea, which are common during treatment, typically resolve as drug levels fall. This is one reason doctors may recommend continuing with lifestyle changes during and after treatment to help maintain results.

There are several situations where knowing the clearance timeline is particularly important.

Before surgery: Some surgeons request that GLP-1 receptor agonists be stopped before procedures involving general anaesthesia, due to the medication’s effect on gastric emptying. Current guidance from the Royal College of Anaesthetists suggests discussing this with your surgical and anaesthetic team. A washout period of at least three weeks is commonly recommended, though your surgeon will advise on the specific timeframe for your procedure.

Pregnancy planning: Tirzepatide is not recommended during pregnancy. Eli Lilly advises stopping the medication at least one month (approximately 25 days or five half-lives) before attempting to conceive. If you are planning a pregnancy, speak with your prescribing doctor to plan the transition safely.

Switching medications: If you are transitioning to another GLP-1 medication such as semaglutide, your doctor may advise starting the new treatment one week after your last Mounjaro dose to maintain therapeutic continuity.

The half-life of tirzepatide remains relatively consistent across doses, from 2.5 mg up to 15 mg. Higher doses result in greater peak concentrations, but the elimination rate stays roughly the same. This means the 25-day clearance window applies regardless of which dose you are on.

However, patients on higher doses may notice stronger residual effects during the first week or two after stopping, simply because there is more of the drug to clear.

Standard workplace or clinical drug screens do not test for tirzepatide. These tests typically look for substances such as opioids, amphetamines, and cannabis. Mounjaro will not cause a positive result on a routine drug test.

Specialised laboratory assays can detect tirzepatide if specifically requested, but this is not part of standard testing.

Research consistently shows that weight regain is common after stopping GLP-1 medications, including tirzepatide. Studies indicate that patients may regain a significant proportion of lost weight within 12 months of discontinuation if no other interventions are in place.

This is why at CutKilo, our doctors work with patients to establish sustainable dietary and exercise habits alongside medication, so that the transition off treatment is as smooth as possible. If you are considering stopping, your prescribing doctor can help create a tapering plan and ongoing support strategy.

If you are planning to stop Mounjaro for any reason, always discuss it with your prescribing doctor first. Abruptly stopping without medical guidance can lead to rapid changes in blood sugar or weight that are best managed with professional support.

At CutKilo, every patient has direct access to their prescribing doctor throughout treatment and beyond. If you are considering Mounjaro and want to understand the full treatment journey, including what happens when you stop, complete our online assessment to find out if you are eligible.

CutKilo is a doctor-led medical weight loss service based at 86 Harley Street, London. Our supervised Mounjaro programme includes regular check-ins, blood monitoring, and ongoing clinical support. Complete your free online assessment today to find out if you are eligible.